For a while, there were none. Suddenly, there were two.
Bicara Therapeutics filed Thursday afternoon for an initial public offering, just …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Teva is continuing its “pivot to growth” initiative by marking an increase in revenue for the second quarter. The pharma revealed its Q2 results on
Amgen offered a glance at plans for its obesity drug candidate MariTide during its fourth-quarter earnings call, including the extension of an ongoing Phase II
An organization devoted to educating future doctors about conflicts of interest will now accept industry funding due to financial stress, prompting outrage from former members